Emergent Biosolutions (EBS) – Investment Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Emergent Biosolutions (NYSE: EBS) recently:

• 8/21/2026 – Emergent Biosolutions was upgraded by Weiss Ratings from “sell (d-)” to “sell (d)”.
• 8/21/2026 – Emergent Biosolutions is now covered by JPMorgan Chase & Co.. They set an “underweight” rating on the stock.
• 8/11/2026 – Emergent Biosolutions was upgraded by Zacks Research to “hold”.
• 8/10/2026 – Emergent Biosolutions had its price target lowered by HC Wainwright from $12.00 to $10.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Emergent Biosolutions had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling

In other Emergent Biosolutions news, SVP Paul Anthony Williams sold 3,000 shares of Emergent Biosolutions stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total transaction of $25,200.00. Following the completion of the transaction, the senior vice president directly owned 159,098 shares of the company’s stock, valued at $1,336,423.20. The trade was a 1.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is currently owned by company insiders.

Get Emergent Biosolutions Inc alerts:

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.

Read More

• Five stocks we like better than Emergent Biosolutions
• Meta’s $18 Billion Settlement May Be a Win for Investors
• Intuit’s Earnings Reset May Be More Pivot Than Plunge
• Salesforce Turns the Corner as AI Fears Start to Fade
• Could Falling Yields Make REIT Stocks Worth a Second Look?

Receive News & Ratings for Emergent Biosolutions Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc and related companies with MarketBeat.com's FREE daily email newsletter.